Home > Healthcare > Medical Devices > Therapeutic Devices > perfusion systems market
Get a free sample of Perfusion Systems Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Perfusion Systems Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Some of the major players operating in the perfusion systems market are :
These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers. These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
Some of the top perfusion system providers are ALA Scientific Instruments, Inc., Bioptechs Inc., Cytiva, Getinge AB, Harvard Bioscience, Inc., Lifeline Scientific, Inc., LivaNova, Medtronic, plc, Merck KGaA, Nipro Corporation, Repligen Corporation, Spectrum Laboratories, Inc., and Terumo Corporation.
North America perfusion systems market was valued at USD 477 million in 2022 and is poised to exhibit considerable growth between 2023 and 2032 driven by the number of patients suffering from cardiovascular and respiratory diseases in the region.
The oxygenators component segment in the perfusion systems industry accounted for USD 399 million in 2022 and is estimated to witness high demand through 2032 attributed to the rising number of cardiac surgeries and the increasing need for CPB.
The market size of perfusion systems was worth more than USD 1.35 billion in 2023 and is anticipated to reach USD 2.02 billion by 2032 owing to the increasing prevalence of cardiovascular and respiratory diseases.